Oral antidiabetic drugs for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 2

table network network 2

display ongoing demontrated benefit only

popup

Rhee (National Health Insurance Review and Assessment Service of Korea), 2021

DPP-4 inhibitor vs. control

COVID 19 all comers

Noh, 2021

DPP-4 inhibitor vs. control

COVID 19 all comers

Strollo, 2021

DPP-4 inhibitor vs. control

COVID 19 all comers

Rhee (National Health Insurance Service database), 2021

DPP-4 inhibitor vs. control

COVID 19 all comers

DARE-19, 2021 NCT04350593

dapagliflozin vs. placebo

COVID 19 hospitalized

Fadini, 2020

DPP-4 inhibitor vs. control

COVID 19 hospitalized

CORONADO, 2020 NCT04324736

DPP-4 inhibitor vs. control

COVID 19 hospitalized

Guardado-Mendoza, 2022 NCT04542213

DPP-4 inhibitor vs. standard of care

COVID 19 hospitalized

Abuhasira, 2021 NCT04371978

DPP-4 inhibitor vs. standard of care

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open